SEGMENTED INFORMATION (Tables)

9 Months Ended

Sep. 30, 2023

SEGMENTED INFORMATION

Schedule of Segmented Revenue and Net Profit/(Loss)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2023
REVENUE	$	28,468		$	7,469,271		$	-		$	7,497,739
COST OF REVENUE		(14,849	)		(6,419,947	)		-			(6,434,796	)
GROSS PROFIT		13,619			1,049,324			-			1,062,943
OTHER INCOME		3,922			507,870			-			511,792
OPERATING EXPENSES
General and administrative		(170,590	)		(2,348,127	)		(1,907,360	)		(4,426,077	)
LOSS FROM OPERATIONS		(153,049	)		(790,933	)		(1,907,360	)		(2,851,342	)
FINANCE COSTS		(2,952	)		(6,794	)		-			(9,746	)
LOSS BEFORE TAX		(156,001	)		(797,727	)		(1,907,360	)		(2,861,088	)
Tax expense		-			(76,418	)		-			(76,418	)
NET LOSS	$	(156,001	)	$	(874,145	)	$	(1,907,360	)	$	(2,937,506	)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2022
REVENUE	$	39,409		$	8,049,723		$	-		$	8,089,132
COST OF REVENUE		(19,173	)		(7,150,156	)		-			(7,169,329	)
GROSS PROFIT		20,236			899,567			-			919,803
OTHER INCOME		6,617			146,720			3			153,340
OPERATING EXPENSES
General and administrative		(157,686	)		(906,698	)		(177,247	)		(1,241,631	)
(LOSS)/PROFIT FROM OPERATIONS		(130,833	)		139,589			(177,244	)		(168,488	)
FINANCE COSTS		(2,196	)		(5,521	)		-			(7,717	)
(LOSS)/PROFIT BEFORE TAX		(133,029	)		134,068			(177,244	)		(176,205	)
Tax expense		-			(22,792	)		-			(22,792	)
(LOSS)/PROFIT AFTER TAX	$	(133,029	)	$	111,276		$	(177,244	)	$	(198,997	)

	As of September 30, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022
BGLC & MRNA Scientific	$	5,002,908	$	677,477	$	176,805	$	108,390
Chemrex		6,462,614		8,062,685		1,601,002		1,966,759
TOTAL		11,465,522		8,740,162		1,777,807		2,075,149